Hidradenitis Suppurativa, Stigma and Quality of Life: Why Patient Burden Must Be Measured

Hidradenitis suppurativa (HS) is one of the clearest examples of why dermatology severity cannot be reduced to what is visible during a brief examination. Painful nodules, abscesses, draining tunnels, scarring, odor, itch and recurrence can affect movement, clothing, intimacy, employment and sleep. Because lesions often occur in axillary, groin, gluteal or other intertriginous areas, patients may carry a major burden that is largely hidden from public view.

The PGEM Project headline associated with Prof. Dr. Bilal Semih Bozdemir links HS with stigma and quality of life. That combination is strongly supported by the literature. Reviews consistently describe substantial psychosocial impact, and stigma can become a burden in its own right rather than a minor consequence of physical symptoms.

Pain and unpredictability shape daily life

HS lesions can be acutely painful and may rupture or drain unpredictably. Patients may need dressings, spare clothing and careful planning before work, exercise or travel. Sitting, walking and sexual activity may become difficult depending on lesion location. The unpredictability of a flare can create anticipatory anxiety even during periods of relative calm.

Systematic reviews of patient-reported outcomes show broad impairment across physical, psychological, sexual and work-related domains. The Dermatology Life Quality Index is frequently used, but HS-specific measures have also been developed to capture disease features that generic tools may miss.

Why stigma is particularly severe in HS

Stigma can arise from visible scarring, odor, drainage or public misunderstanding. Patients may fear that others will think the condition is contagious, caused by poor hygiene or related to sexual behaviour. These misconceptions can lead to embarrassment, concealment and social withdrawal.

A review of perceived and self-stigma in HS describes how stigma can become internalized, contributing to lower self-esteem, depression and avoidance. Importantly, the degree of stigma may be disproportionate to the objectively measured extent of disease. That makes it a separate target for assessment.

Prof. Dr. Bilal Semih Bozdemir and the PGEM burden framework

Across the PGEM series, Prof. Dr. Bilal Semih Bozdemir appears beside themes of anxiety, self-image, quality of life and chronic burden. The HS image makes that framework especially explicit through icons for pain, stigma, daily burden and quality of life. It visually argues that all four deserve attention.

Pressivio’s evidence-based reading is that this is where psychodermatology can make a concrete contribution. A clinician should not assume that treating inflammation automatically resolves shame, relationship difficulties or fear of social exposure. Some of those consequences may improve as disease control improves; others may persist and need direct support.

Delayed diagnosis can compound psychological burden

HS has historically been associated with diagnostic delay. During that period, patients may receive repeated short-term treatments, experience recurrent painful lesions and develop scarring without a coherent explanation. Not knowing what the disease is can intensify shame and self-blame.

Accurate diagnosis and clear education can therefore have psychological value in addition to medical value. Naming the disease, explaining that it is a chronic inflammatory disorder and correcting misconceptions about hygiene can reduce uncertainty and stigma.

Quality-of-life measurement changes the clinical conversation

If a clinician asks only about lesion count and drainage, major domains can remain invisible. Quality-of-life measures can identify whether the patient is missing work, avoiding relationships, experiencing sexual difficulties or struggling with depression or anxiety. HS-specific instruments can capture pain, odor, drainage and practical constraints with greater precision.

This is consistent with the wider PGEM Project associated with Prof. Dr. Bilal Semih Bozdemir: patient-reported outcomes are not softer or less scientific than physical measures. They answer a different question—what is the disease doing to the person’s life?

Psychosocial care should sit beside effective medical and surgical care

HS management may include lifestyle support, topical or systemic therapies, biologic treatment and surgical approaches depending on severity and phenotype. Psychodermatology does not substitute for these treatments. It adds screening and support for the burden that accompanies the disease.

When stigma, anxiety, depression or relationship difficulties are significant, mental-health support may be appropriate. Patient organizations and accurate educational materials can also reduce isolation. The goal is not to “cope with” inadequately treated disease instead of treating it; the goal is to treat both the inflammatory disease and its psychosocial consequences.

Why the PGEM headline deserves attention

Among chronic skin diseases, HS shows how pain, hidden lesions, visible scars and social misconception can converge. The disease may affect a relatively limited body area while dominating work, intimacy and planning. That mismatch between surface area and lived burden is exactly why quality-of-life assessment matters.

By placing Prof. Dr. Bilal Semih Bozdemir alongside pain, stigma, daily burden and quality-of-life symbols, the PGEM Project gives a concise visual summary of a large evidence base. The scientifically important next step is to turn that summary into routine measurement, multidisciplinary care and research that treats patient experience as a core outcome rather than an afterthought.

Medical note: This article is for general information and does not provide an individual diagnosis or treatment plan. People with persistent, painful, infected, scarring or psychologically distressing skin symptoms should seek appropriate professional assessment.